{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:24:08Z","timestamp":1792445048716,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1016\/j.amjcard.2006.11.018","type":"journal-article","created":{"date-parts":[[2006,11,29]],"date-time":"2006-11-29T16:26:52Z","timestamp":1164817612000},"page":"S22-S31","source":"Crossref","is-referenced-by-count":227,"special_numbering":"S1","title":["Safety Considerations with Niacin Therapy"],"prefix":"10.1016","volume":"99","author":[{"given":"John R.","family":"Guyton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold E.","family":"Bays","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2006.11.018_bib1","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/0026-0495(85)90092-7","article-title":"Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin","volume":"34","author":"Knopp","year":"1985","journal-title":"Metabolism"},{"key":"10.1016\/j.amjcard.2006.11.018_bib2","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0002-9343(99)80185-5","article-title":"The prevalence of side effects with regular and sustained-release nicotinic acid","volume":"99","author":"Gibbons","year":"1995","journal-title":"Am J Med"},{"key":"10.1016\/j.amjcard.2006.11.018_bib3","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/jama.1994.03510330050033","article-title":"A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients","volume":"271","author":"McKenney","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2006.11.018_bib4","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"Clofibrate and niacin in coronary heart disease","volume":"231","year":"1975","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2006.11.018_bib5","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S0002-9149(00)00703-7","article-title":"Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia","volume":"85","author":"Goldberg","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.018_bib6","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1001\/archinte.160.8.1177","article-title":"Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol","volume":"160","author":"Guyton","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjcard.2006.11.018_bib7","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0026-0495(98)90284-0","article-title":"Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia","volume":"47","author":"Knopp","year":"1998","journal-title":"Metabolism"},{"key":"10.1016\/j.amjcard.2006.11.018_bib8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/107424849600100302","article-title":"Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled trial","volume":"1","author":"Morgan","year":"1996","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.amjcard.2006.11.018_bib9","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/1523-1747.ep12499963","article-title":"Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans","volume":"98","author":"Morrow","year":"1992","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.amjcard.2006.11.018_bib10","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/clpt.1991.104","article-title":"Tolerance to nicotinic acid flushing","volume":"50","author":"Stern","year":"1991","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.amjcard.2006.11.018_bib11","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1368-5031.2006.00957.x","article-title":"Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment","volume":"60","author":"Oberwittler","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.amjcard.2006.11.018_bib12","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1073\/pnas.0601574103","article-title":"Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans","volume":"103","author":"Cheng","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.amjcard.2006.11.018_bib13","doi-asserted-by":"crossref","first-page":"996","DOI":"10.7326\/0003-4819-139-12-200312160-00009","article-title":"Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia","volume":"139","author":"Meyers","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjcard.2006.11.018_bib14","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1517\/14656566.5.6.1385","article-title":"Extended-release niacin for modifying the lipoprotein profile","volume":"5","author":"Guyton","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.amjcard.2006.11.018_bib15","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/0003-9861(55)90070-9","article-title":"Influence of nicotinic acid on serum cholesterol in man","volume":"54","author":"Altschul","year":"1955","journal-title":"Arch Biochem"},{"key":"10.1016\/j.amjcard.2006.11.018_bib16","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1001\/jama.1961.03040340010003","article-title":"Nicotinic acid treatment of hypercholesterolemia: comparison of plain and sustained-action preparations and report of two cases of jaundice","volume":"177","author":"Christensen","year":"1961","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2006.11.018_bib17","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00007611-198302000-00023","article-title":"Niacin hepatitis","volume":"76","author":"Patterson","year":"1983","journal-title":"South Med J"},{"key":"10.1016\/j.amjcard.2006.11.018_bib18","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0002-9149(97)01016-3","article-title":"Effects of crystalline nicotinic acid-induced hepatic dysfunction on serum low-density lipoprotein cholesterol and lecithin cholesteryl acyl transferase","volume":"81","author":"Tato","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.018_bib19","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0002-9343(91)90122-E","article-title":"Niacin revisited: clinical observations on an important but underutilized drug","volume":"91","author":"Henkin","year":"1991","journal-title":"Am J Med"},{"key":"10.1016\/j.amjcard.2006.11.018_bib20","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/jama.1990.03450020093033","article-title":"Rechallenge with crystalline niacin after drug-induced hepatitis from sustained-release niacin","volume":"264","author":"Henkin","year":"1990","journal-title":"JAMA"},{"issue":"suppl","key":"10.1016\/j.amjcard.2006.11.018_bib21","first-page":"74U","article-title":"Efficacy and safety of an extended-release niacin (Niaspan); a long-term study","volume":"82","author":"Capuzzi","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.018_bib22","unstructured":"Advicor\u00ae (niacin extended-release\/lovastatin tablets) [prescribing information]. Cranbury, NJ: Kos Pharmaceuticals, Inc.; 2005. Available at: http:\/\/www.advicor.com\/pdf\/advicor_pi_r2.pdf. Accessed July 20, 2006."},{"key":"10.1016\/j.amjcard.2006.11.018_bib23","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1001\/archinte.1992.00400160147030","article-title":"Niacin-induced clotting factor synthesis deficiency with coagulopathy","volume":"152","author":"Dearing","year":"1992","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjcard.2006.11.018_bib24","first-page":"166","article-title":"Dose dependence of nicotinic acid-induced hyperbilirubinemia and its dissociation from hemolysis in Gilbert\u2019s syndrome","volume":"107","author":"Gentile","year":"1986","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.amjcard.2006.11.018_bib25","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0002-9149(98)00448-2","article-title":"Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia","volume":"82","author":"Guyton","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.018_bib26","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/sj.jhh.1001099","article-title":"Effects of nicotinic acid on insulin sensitivity and blood pressure in healthy subjects","volume":"14","author":"Kelly","year":"2000","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.amjcard.2006.11.018_bib27","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3109\/00365519609088812","article-title":"Impact of nicotinic acid treatment on insulin secretion and insulin sensitivity in low and high insulin responders","volume":"56","author":"Alvarsson","year":"1996","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.amjcard.2006.11.018_bib28","doi-asserted-by":"crossref","first-page":"5825","DOI":"10.1210\/jc.2005-0048","article-title":"Effects of short-term experimental insulin resistance and family history of diabetes on pancreatic beta-cell function in nondiabetic individuals","volume":"90","author":"Rasouli","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.amjcard.2006.11.018_bib29","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1210\/jc.2006-0913","article-title":"Impaired beta-cell function in human aging: response to nicotinic acid-induced insulin resistance","volume":"91","author":"Chang","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.amjcard.2006.11.018_bib30","doi-asserted-by":"crossref","first-page":"562","DOI":"10.2337\/diab.38.5.562","article-title":"Increased beta-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance","volume":"38","author":"Kahn","year":"1989","journal-title":"Diabetes"},{"key":"10.1016\/j.amjcard.2006.11.018_bib31","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0026-0495(03)00030-1","article-title":"Nicotinic acid-induced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid content","volume":"52","author":"Poynten","year":"2003","journal-title":"Metabolism"},{"key":"10.1016\/j.amjcard.2006.11.018_bib32","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.amjcard.2005.01.073","article-title":"Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia","volume":"95","author":"Vega","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.018_bib33","doi-asserted-by":"crossref","first-page":"S353","DOI":"10.1016\/S0002-8703(99)70035-9","article-title":"Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom Prospective Diabetes Study (UKPDS 47)","volume":"138","author":"Adler","year":"1999","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2006.11.018_bib34","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1001\/jama.1990.03450060069031","article-title":"Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus","volume":"264","author":"Garg","year":"1990","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2006.11.018_bib35","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jama.284.10.1263","article-title":"Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT [Arterial Disease Multiple Intervention Trial] study","volume":"284","author":"Elam","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2006.11.018_bib36","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/archinte.162.14.1568","article-title":"Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial","volume":"162","author":"Grundy","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjcard.2006.11.018_bib37","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.amjcard.2004.09.013","article-title":"Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project)","volume":"95","author":"Canner","year":"2005","journal-title":"Am J Cardiol"},{"issue":"suppl","key":"10.1016\/j.amjcard.2006.11.018_bib38","doi-asserted-by":"crossref","first-page":"6C","DOI":"10.1016\/j.amjcard.2005.12.006","article-title":"Statin safety: an overview and assessment of the data\u20142005","volume":"97","author":"Bays","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.018_bib39","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.0954-6820.1988.tb15891.x","article-title":"Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid","volume":"223","author":"Carlson","year":"1988","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.amjcard.2006.11.018_bib40","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1001\/jama.1987.03390230069027","article-title":"Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts","volume":"257","author":"Blankenhorn","year":"1987","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2006.11.018_bib41","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1586\/14779072.2.4.485","article-title":"Extended-release niacin\/lovastatin: the first combination product for dyslipidemia","volume":"2","author":"Bays","year":"2004","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.amjcard.2006.11.018_bib42","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1001\/archinte.164.7.697","article-title":"New perspectives on the use of niacin in the treatment of lipid disorders","volume":"164","author":"McKenney","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjcard.2006.11.018_bib43","unstructured":"Niaspan (niacin extended-release tablets) [prescribing information]. Cranbury, NJ: Kos Pharmaceuticals, Inc.; 2005. Available at: http:\/\/www.niaspan.com\/pdf\/niaspan_pi_r1.pdf. Accessed July 20, 2006."},{"key":"10.1016\/j.amjcard.2006.11.018_bib44","doi-asserted-by":"crossref","first-page":"597","DOI":"10.7326\/0003-4819-109-7-597_2","article-title":"Lovastatin, nicotinic acid, and rhabdomyolysis","volume":"109","author":"Reaven","year":"1988","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjcard.2006.11.018_bib45","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00002018-200528030-00007","article-title":"Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy","volume":"28","author":"Ratz Bravo","year":"2005","journal-title":"Drug Saf"},{"issue":"suppl","key":"10.1016\/j.amjcard.2006.11.018_bib46","doi-asserted-by":"crossref","first-page":"27C","DOI":"10.1016\/j.amjcard.2005.12.007","article-title":"Statin safety and drug interactions: clinical implications","volume":"97","author":"Bottorff","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.018_bib47","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1517\/14656566.4.11.1901","article-title":"Pharmacotherapy for dyslipidaemia\u2014current therapies and future agents","volume":"4","author":"Bays","year":"2003","journal-title":"Expert Opin Pharmacother"},{"issue":"suppl","key":"10.1016\/j.amjcard.2006.11.018_bib48","doi-asserted-by":"crossref","first-page":"50K","DOI":"10.1016\/S0002-9149(02)02970-3","article-title":"Combination therapy for dyslipidemia: safety and regulatory considerations","volume":"90","author":"Davidson","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.018_bib49","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0002-9149(03)00007-9","article-title":"Comparison of once-daily, niacin extended-release\/lovastatin with standard doses of atorvastatin and simvastatin (the Advicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE])","volume":"91","author":"Bays","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.018_bib50","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1520-037X.2003.03142.x","article-title":"Once-daily niacin extended release\/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin","volume":"6","author":"Bays","year":"2003","journal-title":"Prev Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.018_bib51","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2006.11.018_bib52","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ebcm.2004.03.031","article-title":"Trial finds that simvastatin plus niacin is safe in people with coronary artery disease and low HDL cholesterol","volume":"8","year":"2004","journal-title":"Evid Based Cardiovasc Med"},{"key":"10.1016\/j.amjcard.2006.11.018_bib53","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.amjcard.2003.10.009","article-title":"Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (the HDL Atherosclerosis Treatment Study)","volume":"93","author":"Zhao","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.018_bib54","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0002-9149(01)02338-4","article-title":"Long-term safety and efficacy of a once-daily niacin\/lovastatin formulation for patients with dyslipidemia","volume":"89","author":"Kashyap","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.018_bib55","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/clc.4960260304","article-title":"A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin","volume":"26","author":"Hunninghake","year":"2003","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.018_bib56","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0002-9149(00)01410-7","article-title":"Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia","volume":"87","author":"Wolfe","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.018_bib57","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.amjcard.2004.04.024","article-title":"Safety and compliance with once-daily niacin extended-release\/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study","volume":"94","author":"Rubenfire","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2006.11.018_bib58","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","article-title":"Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins","volume":"110","author":"Taylor","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2006.11.018_bib59","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ajo.2004.04.072","article-title":"Ocular side effects from herbal medicines and nutritional supplements","volume":"138","author":"Fraunfelder","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.amjcard.2006.11.018_bib60","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.ajo.2004.11.040","article-title":"Cystoid macular edema from niacin typically is not accompanied by fluorescein leakage on angiography","volume":"139","author":"Bressler","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.amjcard.2006.11.018_bib61","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1176\/ajp.126.9.1290","article-title":"Nicotinic acid side effects and toxicity: a review","volume":"126","author":"Mosher","year":"1970","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.amjcard.2006.11.018_bib62","first-page":"179","article-title":"Pharmacologic effects of nicotinic acid on human purine metabolism","volume":"84","author":"Gershon","year":"1974","journal-title":"J Lab Clin Med"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914906022363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914906022363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T03:29:28Z","timestamp":1628134168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914906022363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":62,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["S0002914906022363"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2006.11.018","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2007,3]]}}}